Prostate cancer vaccines: Current status

L. C. Hwang, S. Fein, H. Levitsky, William G Nelson

Research output: Contribution to journalArticle

Abstract

Recent insights into cell-mediated immunotherapy have led to a wave of new trials involving immunotherapy for prostate cancer. Vaccines have evolved from nonspecific immune stimulants like Bacillus Calmette-Guerin (BCG) to much more specific and potent strategies. Techniques currently being investigated include passive immunotherapy with monoclonal antibodies, adoptive transfer of activated effector T cells, and active immunotherapy involving immunization with whole-cell or antigen-specific vaccines. These therapies are being modified with cytokines and other immune modulating agents. Understanding the mechanisms of antitumor immunity and identifying relevant tumor-specific antigens will likely improve these vaccine strategies and provide them with a niche in the future of prostate cancer therapy.

Original languageEnglish (US)
Pages (from-to)192-201
Number of pages10
JournalSeminars in Oncology
Volume26
Issue number2
StatePublished - 1999
Externally publishedYes

Fingerprint

Cancer Vaccines
Prostatic Neoplasms
Vaccines
Immunotherapy
Active Immunotherapy
Passive Immunization
Adoptive Transfer
Neoplasm Antigens
Mycobacterium bovis
Immunity
Immunization
Monoclonal Antibodies
Cytokines
T-Lymphocytes
Antigens
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Hwang, L. C., Fein, S., Levitsky, H., & Nelson, W. G. (1999). Prostate cancer vaccines: Current status. Seminars in Oncology, 26(2), 192-201.

Prostate cancer vaccines : Current status. / Hwang, L. C.; Fein, S.; Levitsky, H.; Nelson, William G.

In: Seminars in Oncology, Vol. 26, No. 2, 1999, p. 192-201.

Research output: Contribution to journalArticle

Hwang, LC, Fein, S, Levitsky, H & Nelson, WG 1999, 'Prostate cancer vaccines: Current status', Seminars in Oncology, vol. 26, no. 2, pp. 192-201.
Hwang LC, Fein S, Levitsky H, Nelson WG. Prostate cancer vaccines: Current status. Seminars in Oncology. 1999;26(2):192-201.
Hwang, L. C. ; Fein, S. ; Levitsky, H. ; Nelson, William G. / Prostate cancer vaccines : Current status. In: Seminars in Oncology. 1999 ; Vol. 26, No. 2. pp. 192-201.
@article{9d3d83e80fe349428fc9675e46f9c821,
title = "Prostate cancer vaccines: Current status",
abstract = "Recent insights into cell-mediated immunotherapy have led to a wave of new trials involving immunotherapy for prostate cancer. Vaccines have evolved from nonspecific immune stimulants like Bacillus Calmette-Guerin (BCG) to much more specific and potent strategies. Techniques currently being investigated include passive immunotherapy with monoclonal antibodies, adoptive transfer of activated effector T cells, and active immunotherapy involving immunization with whole-cell or antigen-specific vaccines. These therapies are being modified with cytokines and other immune modulating agents. Understanding the mechanisms of antitumor immunity and identifying relevant tumor-specific antigens will likely improve these vaccine strategies and provide them with a niche in the future of prostate cancer therapy.",
author = "Hwang, {L. C.} and S. Fein and H. Levitsky and Nelson, {William G}",
year = "1999",
language = "English (US)",
volume = "26",
pages = "192--201",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Prostate cancer vaccines

T2 - Current status

AU - Hwang, L. C.

AU - Fein, S.

AU - Levitsky, H.

AU - Nelson, William G

PY - 1999

Y1 - 1999

N2 - Recent insights into cell-mediated immunotherapy have led to a wave of new trials involving immunotherapy for prostate cancer. Vaccines have evolved from nonspecific immune stimulants like Bacillus Calmette-Guerin (BCG) to much more specific and potent strategies. Techniques currently being investigated include passive immunotherapy with monoclonal antibodies, adoptive transfer of activated effector T cells, and active immunotherapy involving immunization with whole-cell or antigen-specific vaccines. These therapies are being modified with cytokines and other immune modulating agents. Understanding the mechanisms of antitumor immunity and identifying relevant tumor-specific antigens will likely improve these vaccine strategies and provide them with a niche in the future of prostate cancer therapy.

AB - Recent insights into cell-mediated immunotherapy have led to a wave of new trials involving immunotherapy for prostate cancer. Vaccines have evolved from nonspecific immune stimulants like Bacillus Calmette-Guerin (BCG) to much more specific and potent strategies. Techniques currently being investigated include passive immunotherapy with monoclonal antibodies, adoptive transfer of activated effector T cells, and active immunotherapy involving immunization with whole-cell or antigen-specific vaccines. These therapies are being modified with cytokines and other immune modulating agents. Understanding the mechanisms of antitumor immunity and identifying relevant tumor-specific antigens will likely improve these vaccine strategies and provide them with a niche in the future of prostate cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0032909555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032909555&partnerID=8YFLogxK

M3 - Article

C2 - 10597730

AN - SCOPUS:0032909555

VL - 26

SP - 192

EP - 201

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2

ER -